^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hodgkin Lymphoma
    Drug:Anniko (penpulimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Akeso Biopharma Press Release
    Title:

    Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

    Published date:
    08/05/2021
    Excerpt:
    Akeso, Inc....announced that the anti PD-1 monoclonal antibody drug...has obtained marketing approval by the National Medical Products Administration (the “NMPA”) of China, for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.